

## Report from the Annual General Meeting of Surgical Science Sweden AB (publ)

**At Surgical Science Sweden AB's Annual General Meeting today, the following, amongst other things, was decided:**

- To adopt the Company's and the group's income statements and balance sheets for the financial year 2021, as set out in the annual report. The Board members and the CEO were discharged from liability for the financial year 2021.
- The Board of Directors' proposal for disposition regarding the company's profit was approved. No dividend will be paid for the financial year 2021 and the funds at the disposal of the Annual General Meeting will be carried forward.
- Re-election of Board members Roland Bengtsson, Jan Bengtsson, Thomas Eklund, Tommy Forsell, Henrik Falconer and Elisabeth Hansson, in accordance with the Nomination Committee's proposal. Roland Bengtsson was re-elected Chairman of the Board of Directors.
- Remuneration to Board members shall, in accordance with the Nomination Committee's proposal, be totalling SEK 1,050,000, of which SEK 300,000 to the Chairman of the Board of Directors and SEK 150,000 to each of the other Board members.
- Re-election, in accordance with the Nomination Committee's proposal, of the registered auditing company KPMG AB. The authorized public accountant Jan Malm will continue as auditor in charge.
- Approval of the Board of Directors' proposal to implement a long-term incentive program for employees in the Group. The rationale of the incentive program is e.g. to contribute to higher motivation and commitment among the employees and to retain employees. The program comprises 200,000 warrants corresponding to a dilution of 0.39 percent. To enable the incentive program, the Annual General Meeting also resolved to issue 200,000 warrants to a subsidiary and to approve transfer of these warrants to participants of the program without consideration. Each warrant entitles the holder to subscribe for one (1) new share in the company. The subscription price of the share at the time of the utilisation of the warrant shall correspond to 120 percent of the Surgical Science share's average volume-weighted closing price during the period from and including May 12, 2022 to and including May 25, 2022. The warrants can be exercised by notification of subscription for new shares during the period from and including June 10, 2025 to and including July 10, 2025.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on the issue of shares, corresponding in total to no more than 10 percent of the share capital.

Gothenburg, Sweden, May 12, 2022  
Surgical Science Sweden AB (publ)  
The Board of Directors

**The press release is available in the attachment or via**

<https://surgicalscience.com/aktien/pressmeddelanden/>

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

**For further information, please contact:**

---

Gisli Hennermark, CEO  
Telephone: +46-70-420 83 00  
E-mail: [gisli.hennermark@surgicalscience.com](mailto:gisli.hennermark@surgicalscience.com)

Anna Ahlberg, CFO  
Telephone: +46-70-855 38 35  
E-mail: [anna.ahlberg@surgicalscience.com](mailto:anna.ahlberg@surgicalscience.com)

#### **About Surgical Science Sweden AB (publ)**

---

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)).

#### **Attachments**

---

[Report from the Annual General Meeting of Surgical Science Sweden AB \(publ\)](#)

---